Lilly's Quest for COVID-19 Treatments: NEUTRALIZING ANTIBODIES

Lilly is bringing the full force of its scientific and medical expertise to attack the coronavirus pandemic around the world.

Existing Lilly medicines are being studied to understand their potential in treating complications of COVID-19, and the company is collaborating with two partner companies to discover novel antibody treatments for COVID-19.

The fastest path to discovery and the most effective way to fight disease is often through collaboration and partnership.

In the case of COVID-19, Lilly is working with governments, academic researchers, and partner companies to study neutralizing antibodies in different patient populations.

Key Clinical Trials

Lilly is studying neutralizing antibodies for prevention and treatment of COVID-19 in mild to moderate patients.

Lilly is testing single antibody therapy as well as combinations of antibodies.
The timing for data disclosure from these trials is highly dependent on patient enrollment and any interim efficacy and safety data we may see.

	BLAZE-1	BLAZE-2	ACTIV-2	*ACTIV-3*
STAGE OF COVID-19 ILLNESS	Mild to Moderate	Post-Exposure Prophylaxis	Ambulatory	*Hospitalized*
DRUG	bamlanivimab and bamlanivimab + etesevimab	bamlanivimab	bamlanivimab	*bamlanivimab*
PHASE(S)	Phase 2	Phase 3	Phase 2/3	*Phase 2/3*
TRIAL TYPE	Randomized, double-blind, placebo-controlled trial	Randomized, double-blind, placebo-controlled trial	Multicenter, adaptive, randomized, blinded controlled trials	*Multicenter, adaptive, randomized, blinded controlled trial*[1]
TRIAL GOAL(S)	Reduce hospitalization or death and viral load	Prevent SARS-CoV-2 infection and COVID-19	**Phase 2:** Reduce duration of symptoms and increase patients with undetectable virus in nasopharyngeal swabs **Phase 3:** Prevent hospitalization or death	*Improve recovery of COVID-19*
PARTICIPANTS	Patients recently diagnosed with mild to moderate COVID-19	Residents and staff of skilled nursing and assisted living facilities who are at risk of exposure due to a positive case of COVID-19 at the facility	Non-hospitalized patients with COVID-19	*Hospitalized patients with severe COVID-19*
# OF PARTICIPANTS (estimated)	Over 800	2,400	Master Protocol: Lilly antibody subset, Phase 2: 220 Phase 3: 1,800	*Master Protocol: Lilly antibody subset,* *Phase 2: 300 Phase 3: 700*
LOCATION	U.S.	Various U.S. long-term care facilities	Several hundred international clinical sites. *See a full list at clinicaltrials.gov.*	*Several hundred international clinical sites. See a full list at clinicaltrials.gov.*
STUDY STATUS	Ongoing Initial data submitted to FDA as part of emergency use authorization request	Ongoing	Ongoing	*No additional hospitalized patients will receive bamlanivimab*
SPONSOR COLLABORATORS	• Lilly	• Lilly • National Institute of Allergy and Infectious Diseases (NIAID)	• NIH, NIAID, Operation Warp Speed • Lilly and other contributors	• *NIH, NIAID, Operation Warp Speed* • *Lilly and other contributors*

1. Participants in the ACTIV-3 study were treated with either a study drug (bamlanivimab) plus current standard of care (Remdesivir), or with placebo plus current standard of care (Remdesivir).

For more information, refer to these listings on clinicaltrials.gov or visit lilly.com